Lavipharm
Mr. James Christopoulos is Senior Managing Director at CVC Capital Partners, whom he joined in 2014. CVC Capital Partners is one of the largest investment funds in the world, managing over $80 billion in capital, with a global presence. CVC has a long-standing track record and expertise investing in healthcare services and, in Greece, is the majority shareholder of Metropolitan Hospital, IASO General and Hygeia Group (Hygeia, Mitera, Leto) through its subsidiary Hellenic Healthcare SA. Prior to joining CVC, Mr. Christopoulos worked for ten years at Investcorp International, Inc., where he led investments in services companies. Previously he was in the leveraged finance team at UBS. Mr. Christopoulos holds a bachelor’s degree in Economics from Columbia University, NY and is fluent in Greek, English, French and German.
This person is not in the org chart
This person is not in any offices
Lavipharm
1 followers
Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.